Dimerix (ASX:DXB) said the Independent Data Monitoring Committee (IDMC) completed a seventh review of the Action3 phase three clinical trial safety data, raising no safety concerns and recommending the continuation of the trial, according to a Wednesday filing with the Australian bourse.

The trial is evaluating the safety and efficacy of drug candidate DMX-200 in patients with the kidney disease focal segmental glomerulosclerosis.

The next IDMC meeting is planned for the second quarter of 2026, the filing said.

Shares rose 2% in afternoon trade on Wednesday.